Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Nov 21, 2012

Impax and Perrigo Team Up on Topical Generic

  • Impax Laboratories will collaborate with Perrigo on the development, manufacturing, and commercialization of an extended topical generic drug product with first-to-market potential.

    “In just over two years, Impax has partnered with four different companies on 27 alternative dosage form products, with 18 of these either pending approval at the U.S. Food and Drug Administration or under development,” says Larry Hsu, Ph.D., president and CEO of Impax. “We will continue to focus on delivering growth from high-value products, technologies, and businesses in complementary dosage forms.”

    “This collaboration is yet another example of our long-term investment in development of products in the extended topical space,” adds Perrigo’s chairman, president, and CEO, Joseph C. Papa.

    Impax applies its formulation knowledge and drug delivery technology to the development of controlled-release and specialty generics in addition to the development of branded products. Impax claims to currently manufacture and market 102 generic pharmaceutical products, which represent dosage variations of 30 different pharmaceutical compounds. The firm’s branded pipeline is focused on targeting significant unmet needs in the CNS market including Parkinson’s disease, restless legs syndrome, and spasticity in patients with multiple sclerosis.

    Perrigo develops, manufactures, and distributes over the counter and generic prescription pharmaceuticals, nutritional products, and active pharmaceutical ingredients.



Related content

Be sure to take the GEN Poll

Cancer vs. Zika: What Worries You Most?

While Zika continues to garner a lot of news coverage, a Mayo Clinic survey reveals that Americans believe the country’s most significant healthcare challenge is cancer. Compared to other diseases, does the possibility of developing cancer worry you the most?

More »